These newly identified clock regulators could be targeted at a specific time of day according to their rhythmicity to optimize treatment of the progression of nonalcoholic fatty liver disease (NAFLD) or NASH. This evidence concerns the gene CLOCK and metabolic dysfunction-associated steatotic liver disease.